Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: An observational study

International Journal of Infectious Diseases

Volumn 20, Issue 1, 2014, Pages 42-46

  Al Tawfiq, Jaffar A ^a,b   Momattin, Hisham ^a   Dib, Jean ^a   Memish, Ziad A ^c,d  

^a DHAHRAN HEALTH CENTER   (Saudi Arabia)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MINISTRY OF HEALTH   (Saudi Arabia)

^d ALFAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Interferon; MERS CoV; Pegylated interferon; Ribavirin

Indexed keywords

ALPHA2B INTERFERON; AMYLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CORTICOSTEROID; CREATININE; HEMOGLOBIN; IMIPENEM; LACTATE DEHYDROGENASE; LEVOFLOXACIN; METHYLPREDNISOLONE; OSELTAMIVIR; PREDNISOLONE; PREDNISONE; RIBAVIRIN; TRIACYLGLYCEROL LIPASE;

ADD ON THERAPY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANTIVIRAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CAUSE OF DEATH; CLINICAL ARTICLE; CORONAVIRUS; CORONAVIRUS INFECTION; CORTICOSTEROID THERAPY; COUGHING; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DIABETES MELLITUS; DISEASE COURSE; DYSPNEA; END STAGE RENAL DISEASE; FEMALE; FEVER; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; HYPOXEMIA; KIDNEY DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LOADING DRUG DOSE; MALE; MIDDLE AGED; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; MULTIPLE ORGAN FAILURE; NASOGASTRIC TUBE; OBSERVATIONAL STUDY; PANCREATITIS; PNEUMONIA; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT; COMORBIDITY; DRUG EFFICACY; NONHUMAN; TREATMENT RESPONSE;

INTERFERON; MERS-COV; PEGYLATED INTERFERON; RIBAVIRIN;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CORONAVIRUS; CORONAVIRUS INFECTIONS; CRITICAL ILLNESS; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; IMIPENEM; INTERFERON-ALPHA; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RENAL INSUFFICIENCY, CHRONIC; RESPIRATION, ARTIFICIAL; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896695450     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.12.003     Document Type: Article

References (22)

1. Penttinen P.M., Kaasik-Aaslav K., Friaux A., Donachie A., Sudre B., Amato-Gauci A.J., et al. Taking stock of the first 133 MERS coronavirus cases globally-is the epidemic changing?. Euro Surveill 2013, 18. pii: 20596.
2. World Health Orzination Middle East respiratory syndrome coronavirus (MERS-CoV)-update 2013, WHO, Geneva, Available at: http://www.who.int/csr/don/2013_12_02/en/index.html last (accessed December 3).
3. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367:1814-1820.
4. Omrani A.S., Matin M.A., Haddad Q., Al-Nakhli D., Memish Z.A., Albarrak A.M. A family cluster of Middle East respiratory syndrome coronavirus infections related to a likely unrecognized asymptomatic or mild case. Int J Infect Dis 2013, 17:e668-e672.
5. Assiri A., Al-Tawfiq J.A., Al-Rabeeah A.A., Al-Rabiah F.A., Al-Hajjar S., Al-Barrak A., et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013, 13:752-761.
6. Assiri A., McGeer A., Perl T.M., Price C.S., Al Rabeeah A.A., Cummings D.A., et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013, 369:407-416. KSA MERS-CoV Investigation Team.
7. Memish Z.A., Zumla A.I., Al-Hakeem R.F., Al-Rabeeah A.A., Stephens G.M. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med 2013, 368:2487-2494.
8. Momattin H., Mohammed K., Zumla A., Memish Z.A., Al-Tawfiq J.A. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)-possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis 2013, 17:e792-e798.
9. Corman V.M., Eckerle I., Bleicker T., Zaki A., Landt O., Eschbach-Bludau M., et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill 2012, 17. pii: 20285.
10. Corman V.M., Müller M.A., Costabel U., Timm J., Binger T., Meyer B., et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill 2012, 17. pii: 20334.
11. Hsu L.Y., Lee C.C., Green J.A., Ang B., Paton N.I., Lee L., et al. Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis 2003, 9:713-717.
12. Sung J.J., Wu A., Joynt G.M., Yuen K.Y., Lee N., Chan P.K., et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 2004, 59:414-420.
13. Leong H.N., Ang B., Earnest A., Teoh C., Xu W., Leo Y.S. Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003. Trop Med Int Health 2004, 9:923-927.
14. Poutanen S.M., Low D.E., Henry B., Finkelstein S., Rose D., Green K., et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003, 348:1995-2005.
15. Tsang K.W., Ho P.L., Ooi G.C., Yee W.K., Wang T., Chan-Yeung M., et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003, 348:1977-1985.
16. Peiris J.S., Chu C.M., Cheng V.C., Chan K.S., Hung I.F., Poon L.L., et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003, 361:1767-1772.
17. Zhao Z., Zhang F., Xu M., Huang K., Zhong W., Cai W., et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003, 52:715-720.
18. Adisasmito W., Chan P.K., Lee N., Oner A.F., Gasimov V., Aghayev F., et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a global patient registry. J Infect Dis 2010, 202:1154-1160. 10.1086/656316.
19. Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013 Oct 3. pii: S0163-4453(13)00298-3.
20. Falzarano D., de Wit E., Martellaro C., Callison J., Munster V.J., Feldmann H. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep 2013, 3:1686.
21. Falzarano D., de Wit E., Rasmussen A.L., Feldmann F., Okumura A., Scott D.P., et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013, 19:1313-1317.
22. Product Information: REBETOL (R) oral capsules solution, ribavirin oral capsules solution 2009, Schering Plough Corporation, Kenilworth, NJ.